Market Insights Snapshot
In Colorado, Aliviar has shown notable performance in the Tincture & Sublingual category, displaying consistent upward movement from October 2023 through January 2024. Starting at a rank of 7 in October, Aliviar improved its standing to 5th in November, and further to 4th in December and January. This progression indicates a growing preference for Aliviar's offerings in this category among Colorado consumers. Sales in October were recorded at $25,840, and by January 2024, they saw a significant increase, highlighting the brand's growing market share and consumer trust in their Tincture & Sublingual products.
Similarly, in the Topical category within the same state, Aliviar has maintained a strong presence, albeit with slight fluctuations in its rankings. The brand was ranked 11th in October 2023, improved to 9th in November, dipped to 10th in December, and settled back at 9th in January 2024. These movements suggest a solid but competitive standing in the Topical market segment. Although not leading the category, Aliviar's consistent top 10 performance underscores its relevance and steady demand among consumers looking for topical cannabis solutions. Such performance, coupled with a sales increase from October's $9,806 to January's $14,948, reflects positively on Aliviar's market strategy and product quality in the Topical category.
In the competitive landscape of the Tincture & Sublingual category in Colorado, Aliviar has shown a notable upward trajectory in its ranking over the recent months, moving from 7th place in October 2023 to 4th place by January 2024. This improvement in rank is particularly impressive considering the competitive nature of this market. Escape Artists, a leading competitor, has seen a slight decline from the top position in November 2023 to 3rd by January 2024, despite maintaining high sales volumes. Meanwhile, My Brother's Flower has surged to the 2nd position by January 2024, showcasing the dynamic shifts within this category. Stratos has remained relatively stable, securing the 5th spot consistently towards the end of the period. Care Division, on the other hand, has experienced a decline, moving from 3rd to 6th place. Aliviar's upward movement in rank and its ability to increase sales significantly from November 2023 to January 2024, even surpassing some of its competitors, highlights its growing prominence and potential threat to its competitors in the Colorado Tincture & Sublingual market.
In January 2024, Aliviar's top-selling product was the CBD/THC 20:1 Calm Tincture (1400mg CBD, 70mg THC), maintaining its number one rank from previous months with sales reaching 1233 units. Following closely, the CBD/THC/CBN 5:1:1 Sleep Tincture (250mg CBD, 50mg THC, 50mg CBN, 10ml) secured the second position, showing a positive sales trajectory from its previous third and second ranks in November and December 2023, respectively. The third spot was held by the CBD/THC 2:1 Scented Cream (420mg CBD, 210mg THC, 2oz), which also displayed a consistent performance by maintaining its rank from December. Notably, the CBD/THC 2:1 Unscented Cream and the CBD/THC 2:1 Sport Cream held steady in their fourth and fifth ranks, respectively, indicating a stable demand for topical products. These rankings reflect a consistent consumer preference for tinctures and topicals within Aliviar's product line, with the leading tincture product showing a significant increase in sales from the previous month.